Auris Medical AG, a Swiss-French biotechnology company developing novel therapies for ear disorders, raised CHF 11 million in its Series B financing round from institutional investors. The investment will fund the company’s further expansion and in particular the development of its lead products. The new shares were subscribed by a group of investors led by AGF Private Equity, Paris, and including the two life science investment funds ZKB Pharma Vision Fund, Zurich, and Lacuna Apo Biotech Fund, Luxembourg, as well as an undisclosed industrial company.
